News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novartis International AG Cuts Outlook; US Regulators Extend Tasigna Review
July 17, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, July 17 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX: Quote, Profile, Research) said on Tuesday that U.S. regulators had requested a three-month extension in the regulatory review period for cancer drug Tasigna.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Earnings
Europe
MORE ON THIS TOPIC
Earnings
Sanofi’s Legacy Vaccine Sales Decline As Americans Skip Flu Shots
October 24, 2025
·
2 min read
·
Annalee Armstrong
Earnings
MASH, Metsera Deals Send Analysts Marauding to Viking
October 23, 2025
·
6 min read
·
Annalee Armstrong
Earnings
‘We’re Not Done’: Roche Plans To Sustain Dealmaking Pace After 89bio
October 23, 2025
·
2 min read
·
Tristan Manalac
Cystic fibrosis
Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug
October 23, 2025
·
2 min read
·
Tristan Manalac
